Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 1:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 437 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Results available

Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma

NCT01186978
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Radiation Therapy
Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
3
States / cities
Durham, North Carolina • Raleigh, North Carolina
Active, not recruiting Not applicable Interventional

Proton Radiation Therapy for Gliomas

NCT01358058
Conditions
Low Grade Glioma, WHO Grade 3 Glioma With IDH1 Mutation, WHO Grade 3 Glioma With 1p/19q Codeletion
Interventions
Proton radiation
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
chemotherapy, total-body irradiation, peripheral blood stem cell transplantation, cyclosporine, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, therapeutic allogeneic lymphocytes
Drug · Radiation · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
3
States / cities
Duarte, California • Stanford, California • Seattle, Washington
Conditions
Retinoblastoma, Retinal Neoplasm
Interventions
Enucleation, Vincristine, Carboplatin, Focal Therapies, External Beam Radiation, Vincristine and Topotecan, Vincristine + Carboplatin + Etoposide, vincristine, cyclophosphamide, and doxorubicin, Vincristine, Carboplatin and Etoposide, Periocular carboplatin, G-CSF
Procedure · Drug · Radiation + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions
Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
Drug · Other · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
3
States / cities
Salt Lake City, Utah • Seattle, Washington
Conditions
Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure, Short Telomere Length, Fanconi Anemia, Non Fanconi DNA-DSB Repair Disorder, Hoyeraal-Hreidarsson Syndrome, Dyskeratosis Congenita, Telomere Biology Disorder, Short Telomere Syndrome
Interventions
Alemtuzumab, Fludarabine, Melphalan, Low Dose Total Body Irradiation, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
4 Months to 50 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
SARS-CoV 2
Interventions
Phase 1, Phase 2
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias

NCT00061568
Conditions
Congenital Hemolytic Anemia, Sickle Cell Disease
Interventions
Peripheral blood hematopoietic progenitor cell (PBPC) transplant, Alemtuzumab, Peripheral blood hematopoietic progenitor cell Apheresis, Sirolimus
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Cisplatin, Carboplatin, IMRT (Intensity-Modulated Radiation Therapy), Boost Radiation to Hypoperfused Volumes
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan
Conditions
Alzheimer Disease
Interventions
Challenge A - low calorie Ensure®, Challenge B - Ensure® plus ketone esters (KE), PET Scan, Cognitive Testing - FCSRT, Story Recall, BVRT, CogState One Card Learning
Dietary Supplement · Procedure · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Lung Cancer, Breast Cancer, Mediastinum Lesion, Radiation Pneumonitis
Interventions
4D Computed Tomography (CT), Cone Beam CT, Low-dose Cinefluorography, Pulmonary Function Tests
Radiation · Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma (NHL), Hodgkin's Lymphoma
Interventions
Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative), Fludarabine, Melphalan, ATG (Reduced Intensity)
Drug
Lead sponsor
Targazyme, Inc.
Industry
Eligibility
1 Year to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
4
States / cities
La Jolla, California • Cleveland, Ohio • Houston, Texas + 1 more
Conditions
Non Small Cell Lung Cancer
Interventions
Viagenpumatucel-L, Metronomic Cyclophosphamide, Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)
Drug
Lead sponsor
Heat Biologics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Rogers, Arkansas • La Jolla, California • Los Angeles, California + 13 more
Conditions
Prostate Cancer
Interventions
Proton Radiation Hypofractionation, Proton Radiation Standard Fractionation
Radiation
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
Phoenix, Arizona • Warrenville, Illinois • Baltimore, Maryland + 2 more
Conditions
T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Interventions
Asparaginase, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
1,895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
191
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
Conditions
Metastatic Cancer
Interventions
Palliative radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease, Peripheral T-cell Lymphoma
Interventions
Pentostatin, Total-body irradiation (TBI), Cyclosporine A (CsA), Mycophenolate Mofetil (MMF), G-CSF
Drug · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
ISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Pembrolizumab, Radiation Therapy
Biological · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain
Interventions
Method(s)1 Attribution, Method(s)2 Attribution,
Drug
Lead sponsor
DR. DIANE CHISESI NFS. MD. PHD.
Other
Eligibility
44 Years to 59 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Colorado Springs, Colorado
Recruiting Not applicable Interventional

Stiffness and Low Dose Irradiation RCT

NCT07767097
Conditions
Arthrofibrosis of Knee
Interventions
Low-Dose External Beam Irradiation, Hinged Revision Total Knee Arthroplasty
Radiation · Procedure
Lead sponsor
Mount Sinai Hospital, Canada
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Los Angeles, California • Salt Lake City, Utah
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
Brachytherapy, Stereotactic Body Radiation Therapy, Quality-of-life assessment, Questionnaire administration
Radiation · Procedure · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2040
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed No phase listed Observational

Prognosis of Very Low Dose SPECT

NCT01387152
Conditions
Chest Pain
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Glioblastoma Multiforme of Brain
Interventions
TVI-Brain-1, Standard of Care, Radiotherapy, Temozolomide
Biological · Procedure · Radiation + 1 more
Lead sponsor
TVAX Biomedical
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Tampa, Florida + 4 more
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
Treosulfan
Drug
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
Up to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 19 more